🇩🇪#BNTX #отчетность
BioNTech Q1 23 Earnings:
- EPS EU2.05 (est EU0.69)
- Rev EU1.28B (est EU1.12B)
- Oper Income EU654.4M (est EU231.8M)
- Still Sees FY R&D Expenses EU2.40B To EU2.60B (est EU2.5B)
- Still Sees FY COVID-19 Vaccine Rev About EU5B